 |
||||
|
||||
|
||||
|
||||
Previous Article | Next Article
The Journal of Neuroscience, June 15, 1999, 19(12):5096-5107
Altered Serotonin Innervation Patterns in the Forebrain of Monkeys Treated with (±)3,4-Methylenedioxymethamphetamine Seven Years Previously: Factors Influencing Abnormal Recovery
George Hatzidimitriou1, Una D. McCann2, and George A. Ricaurte1 1 Department of Neurology, The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205, and 2 Unit on Anxiety Disorders, Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, Maryland 20892
The recreational drug (±)3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") is a potent and selective brain serotonin (5-HT) neurotoxin in animals and, possibly, in humans. The purpose of the present study was to determine whether brain 5-HT deficits persist in squirrel monkeys beyond the 18-month period studied previously and to identify factors that influence recovery of injured 5-HT axons. Seven years after treatment, abnormal brain 5-HT innervation patterns were still evident in MDMA-treated monkeys, although 5-HT deficits in some regions were less severe than those observed at 18 months. No loss of 5-HT nerve cell bodies in the rostral raphe nuclei was found, indicating that abnormal innervation patterns in MDMA-treated monkeys are not the result of loss of a particular 5-HT nerve cell group. Factors that influence recovery of 5-HT axons after MDMA injury are (1) the distance of the affected axon terminal field from the rostral raphe nuclei, (2) the degree of initial 5-HT axonal injury, and possibly (3) the proximity of damaged 5-HT axons to myelinated fiber tracts. Additional studies are needed to better understand these and other factors that influence the response of primate 5-HT neurons to MDMA injury and to determine whether the present findings generalize to humans who use MDMA for recreational purposes.
Key words: amphetamines; methylenedioxymethamphetamine; serotonin; neurotoxicity; regeneration; 5-HT axon
Copyright © 1999 Society for Neuroscience 0270-6474/99/19125096-12$05.00/0
This article has been cited by other articles:
E. Alves, T. Summavielle, C. J. Alves, J. Gomes-da-Silva, J. C. Barata, E. Fernandes, M. de Lourdes Bastos, M. A. Tavares, and F. Carvalho
Monoamine Oxidase-B Mediates Ecstasy-Induced Neurotoxic Effects to Adolescent Rat Brain Mitochondria
J. Neurosci., September 19, 2007; 27(38): 10203 - 10210.
[Abstract] [Full Text] [PDF]
T. Schilt, M. M. L. de Win, M. Koeter, G. Jager, D. J. Korf, W. van den Brink, and B. Schmand
Cognition in Novice Ecstasy Users With Minimal Exposure to Other Drugs: A Prospective Cohort Study
Arch Gen Psychiatry, June 1, 2007; 64(6): 728 - 736.
[Abstract] [Full Text] [PDF]
M. J. Sabatini, P. Ebert, D. A. Lewis, P. Levitt, J. L. Cameron, and K. Mirnics
Amygdala Gene Expression Correlates of Social Behavior in Monkeys Experiencing Maternal Separation
J. Neurosci., March 21, 2007; 27(12): 3295 - 3304.
[Abstract] [Full Text] [PDF]
B. B. Quednow, F. Jessen, K.-U. Kuhn, W. Maier, I. Daum, and M. Wagner
Memory deficits in abstinent MDMA (ecstasy) users: neuropsychological evidence of frontal dysfunction
J Psychopharmacol, May 1, 2006; 20(3): 373 - 384.
[Abstract] [PDF]
L. Reneman, T. Schilt, M. M. de Win, J. Booij, B. Schmand, W. v. den Brink, and O. Bakker
Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users
J Psychopharmacol, May 1, 2006; 20(3): 389 - 399.
[Abstract] [PDF]
L. Reneman, M. M. L. de Win, W. van den Brink, J. Booij, and G. J. den Heeten
Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects
J Psychopharmacol, March 1, 2006; 20(2): 164 - 175.
[Abstract] [PDF]
E. Gouzoulis-Mayfrank and J. Daumann
The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview
J Psychopharmacol, March 1, 2006; 20(2): 188 - 193.
[Abstract] [PDF]
N. Easton and C. A. Marsden
Ecstasy: Are animal data consistent between species and can they translate to humans?
J Psychopharmacol, March 1, 2006; 20(2): 194 - 210.
[Abstract] [PDF]
J. Daumann, B. Till, T. Fischermann, M. Rezk, and E. Gouzoulis-Mayfrank
Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study
J Psychopharmacol, March 1, 2006; 20(2): 236 - 244.
[Abstract] [PDF]
S. L. Verheyden, R. Maidment, and H. V. Curran
Quitting Ecstasy: An Investigation of Why People Stop Taking the Drug and Their Subsequent Mental Health
J Psychopharmacol, December 1, 2003; 17(4): 371 - 378.
[Abstract] [PDF]
A. R. Green, A. O. Mechan, J. M. Elliott, E. O'Shea, and M. I. Colado
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy")
Pharmacol. Rev., September 1, 2003; 55(3): 463 - 508.
[Abstract] [Full Text] [PDF]
R. Buchert, R. Thomasius, B. Nebeling, K. Petersen, J. Obrocki, L. Jenicke, F. Wilke, L. Wartberg, P. Zapletalova, and M. Clausen
Long-Term Effects of "Ecstasy" Use on Serotonin Transporters of the Brain Investigated by PET
J. Nucl. Med., March 1, 2003; 44(3): 375 - 384.
[Abstract] [Full Text] [PDF]
Z. Szabo, U. D. McCann, A. A. Wilson, U. Scheffel, T. Owonikoko, W. B. Mathews, H. T. Ravert, J. Hilton, R. F. Dannals, and G. A. Ricaurte
Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions
J. Nucl. Med., May 1, 2002; 43(5): 678 - 692.
[Abstract] [Full Text] [PDF]
L. Reneman, C. B. L. M. Majoie, H. Flick, and G. J. den Heeten
Reduced N-Acetylaspartate Levels in the Frontal Cortex of 3,4-Methylenedioxymethamphetamine (Ecstasy) Users: Preliminary Results
AJNR Am. J. Neuroradiol., February 1, 2002; 23(2): 231 - 237.
[Abstract] [Full Text] [PDF]
T. Xie, L. Tong, T. Barrett, J. Yuan, G. Hatzidimitriou, U. D. McCann, K. G. Becker, D. M. Donovan, and G. A. Ricaurte
Changes in Gene Expression Linked to Methamphetamine-Induced Dopaminergic Neurotoxicity
J. Neurosci., January 1, 2002; 22(1): 274 - 283.
[Abstract] [Full Text] [PDF]
R. J. Croft, A. Klugman, T. Baldeweg, and J. H. Gruzelier
Electrophysiological Evidence of Serotonergic Impairment in Long-Term MDMA (""Ecstasy"") Users
Am J Psychiatry, October 1, 2001; 158(10): 1687 - 1692.
[Abstract] [Full Text] [PDF]
L. Reneman, J. Lavalaye, B. Schmand, F. A. de Wolff, W. van den Brink, G. J. den Heeten, and J. Booij
Cortical Serotonin Transporter Density and Verbal Memory in Individuals Who Stopped Using 3,4-Methylenedioxymethamphetamine (MDMA or "Ecstasy"): Preliminary Findings
Arch Gen Psychiatry, October 1, 2001; 58(10): 901 - 906.
[Abstract] [Full Text] [PDF]
U. D. McCann, G. A. Ricaurte, and M. E. Molliver
"Ecstasy" and Serotonin Neurotoxicity: New Findings Raise More Questions
Arch Gen Psychiatry, October 1, 2001; 58(10): 907 - 908.
[Full Text] [PDF]
L. Reneman, C. B. L. M. Majoie, J. B. A. Habraken, and G. J. den Heeten
Effects of Ecstasy (MDMA) on the Brain in Abstinent Users: Initial Observations with Diffusion and Perfusion MR Imaging
Radiology, September 1, 2001; 220(3): 611 - 617.
[Abstract] [Full Text] [PDF]
E. Gouzoulis-Mayfrank, J. Daumann, F. Tuchtenhagen, S. Pelz, S. Becker, H.-J. Kunert, B. Fimm, and H. Sass
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA)
J. Neurol. Neurosurg. Psychiatry, June 1, 2000; 68(6): 719 - 725.
[Abstract] [Full Text] [PDF]
|
|
|
|
 |
|